English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe incidence of non-alcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease (ALD) is increasing year by year due to changes in the contemporary environment and dietary structure, and is an important public health problem
Tag: Hepatocellular Carcinoma
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4
New study reveals how gender affects liver transplant success in cancer patients
A groundbreaking multicenter cohort study in China has illuminated the impact of sex on the outcomes of liver transplantation (LT) for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Combined therapy makes headway for liver cancer
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial conducted by UT Southwestern Medical Center.
Promising Personalized Approach to Liver Cancer Therapy Made Possible by DNA-based Neoantigen Research Designed at The Wistar Institute
Results of a new clinical trial published in Nature Medicine show that a novel, personalized neoantigen vaccine therapy demonstrated promising anti-tumor efficacy in patients with liver cancer who failed their original front-line treatment. The foundational biomedical research leading to this important study and important outcome originated from research in the Vaccine & Immunotherapy Center at The Wistar Institute.
Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial
Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma.
Study: Race, Ethnicity May Play a Role in Cause of Liver Cancer
Race and ethnicity may play a role in liver cancer, which disproportionately affects people of low socioeconomic status, as well as immigrants, veterans and incarcerated populations.
Liver cancer treatment costly for Medicare patients, UT Southwestern study finds
Hepatocellular carcinoma (HCC), the most common type of liver cancer, can place a significant financial burden on patients, according to an analysis led by a researcher at UT Southwestern Medical Center.
Adding radiation to systemic therapy extends overall survival for patients with advanced liver cancer
Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients’ quality of life, a randomized phase III clinical trial shows.
Transcutaneous Electrical Acustimulation for IBS-C, Infliximab Retreatment for Crohn’s Disease Featured in September Issue of AJG
The September issue of AJG highlights new clinical science, including a potential therapy to improve IBS-C symptoms, reintroduction of infliximab for Crohn’s disease, and population-based data to examine incidence and mortality of certain GI and hepatology diseases.
New Study Shows Hope, Options for Older Patients With Liver Cancer
Physicians and researchers from UK HealthCare’s Transplant Center and the University of Kentucky Markey Cancer Center conducted a study of patients over the age of 70 with a type of liver cancer called hepatocellular carcinoma (HCC) and how the outcomes of ablative treatments compare to liver transplants. The findings were published in the May 2022 issue of the Journal of the American College of Surgeons.
A Target for Potential Cancer Drugs May, In Fact, Worsen Disease
Researchers reveal a previously unrealized complexity in cancer development, one that raises concerns and caution about targeting an enzyme popular in oncological treatments.
External-beam radiation therapy underused for people with liver cancer awaiting transplant
People with liver cancer awaiting transplantation could benefit from non-invasive radiation treatments but are rarely given this therapy, according to a new analysis of U.S. national data. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
MD Anderson Research Highlights for June 16, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) infections.
Diet Plays Critical Role in NASH Progressing to Liver Cancer in Mouse Model
Researchers at University of California San Diego School of Medicine found in a mouse model that when fed a Western diet rich in calories, fat and cholesterol, the mice progressively became obese, diabetic and developed NASH, which progressed to HCC, chronic kidney and cardiovascular disease.
Study Explores Changes in Liver Cancer Cell Metabolism in Response to Galactose Sugar
Article title: Global changes to HepG2 cell metabolism in response to galactose treatment Authors: Robert A. Skolik, Jason Solocinski, Mary E. Konkle, Nilay Chakraborty, Michael A. Menze From the authors: “Here we demonstrate that the metabolic poise in tumor-derived HepG2 cells…
Researcher Developing Scoring System to Redefine How U.S. Patients are Prioritized for Liver Transplant
Researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are collaborating with faculty at the University of Pennsylvania to develop a risk score that more comprehensively prioritizes liver cancer patients for transplantation.
New Cases of Hepatocellular Carcinoma Disproportionately Affecting Americans in Rural Areas New Study Shows
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that the rate of new hepatocellular carcinoma (HCC) cases has slowed since 2009, but only in urban areas. Rural non-Hispanic whites and Blacks have experienced the greatest increases over time when comparing rural and urban HCC trends by specific demographic factors.
Chemotherapy Drug More Effective When Combined With Microbubbles
Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering.
A Healthy Lifestyle May Help Prevent Liver-Related Deaths
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a substantial burden of hepatocellular carcinoma (HCC) and cirrhosis-related deaths may be prevented by lifestyle modifications to diet, alcohol use and exercise.